Astellas Pharma Valuation Multiples

Astellas Pharma Overview

About Astellas Pharma

Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.

Founded

1939

HQ

Employees

13.6K

Website

astellas.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $14B

EBITDA: $4B

EV

$32B

Valuation Multiples

Multiples.vc

Start free trial

Astellas Pharma Financials

Astellas Pharma reported last 12-month revenue of $14B and EBITDA of $4B.

In the same LTM period, Astellas Pharma generated $11B in gross profit, $4B in EBITDA, and $2B in net income.

Astellas Pharma P&L

In the most recent fiscal year, Astellas Pharma reported revenue of $13B and EBITDA of $3B.

Astellas Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX

Astellas Pharma Stock Performance

Astellas Pharma has current market cap of $29B, and enterprise value of $32B.

Astellas Pharma's stock price is $16.04.

Astellas Pharma Valuation Multiples

Astellas Pharma trades at 2.3x EV/Revenue multiple, and 8.2x EV/EBITDA.

Astellas Pharma Financial Valuation Multiples

As of April 18, 2026, Astellas Pharma has market cap of $29B and EV of $32B.

Equity research analysts estimate Astellas Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Astellas Pharma has a P/E ratio of 16.1x.

Astellas Pharma Margins & Growth Rates

Astellas Pharma's revenue in the last 12 month grew by 5%.

Astellas Pharma's revenue per employee in the last FY averaged $1.0M, while opex per employee averaged $0.7M for the same period.

Astellas Pharma's rule of 40 is 37% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Astellas Pharma's rule of X is 48% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Astellas Pharma Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Astellas Pharma M&A Activity

Astellas Pharma acquired XXX companies to date.

Last acquisition by Astellas Pharma was on XXXXXXXX, XXXXX. Astellas Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Astellas Pharma Investment Activity

Astellas Pharma invested in XXX companies to date.

Astellas Pharma made its latest investment on XXXXXXXX, XXXXX. Astellas Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).